Abiopharma

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time

Clinical trial NCT05722444 updates: 1. status: UNKNOWN → COMPLETED 2. completion date: 2024-05-31 → 2024-10-17 3. primary completion date: 2024-04-30 → 2024-04-10

Clinical trial NCT07224529 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-05-01 → 2026-06-01

Clinical trial NCT07370467 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. completion date: 2026-01-30 → 2026-09-30 3. primary completion date: 2026-01-30 → 2026-09-30

Clinical trial NCT06947408 updates: 1. status: RECRUITING → COMPLETED 2. completion date: 2026-04-23 → 2026-05-11 3. primary completion date: 2026-04-23 → 2026-05-11 4. enrollment: 60 → 44 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT06097728 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. primary completion date: 2027-11-19 → 2028-11-16 3. enrollment: 825 → 861 participants 4. enrollment type: ESTIMATED → ACTUAL

Atos Group et Microsoft étendent leur collaboration stratégique pour déployer une IA agentique sécurisée auprès des collaborateurs et des clients du Groupe

Syntec Optics (Nasdaq: OPTX) Secures $4.6M Critical-Care Biomedical Order

Atos Group and Microsoft Expand Strategic Collaboration to Scale Secure Agentic AI Across Atos Group Workforce and Clients

SEALSQ to Join High-Level Roundtable on Quantum Migration and Cybersecurity Transitions at CEA-Leti Innovation Days (LID) World Summit 2026